Bristol-Myers Squibb’s (BMY) immunoscience business is represented by the drug Orencia. Let’s take a look at Orencia’s revenue over the last few quarters.
Orencia is a fusion protein used for the treatment of rheumatoid arthritis and related indications. Orencia’s revenue was $650 million in 2Q17, a 10% rise compared to $593 million in 2Q16, following its strong performance in both the United States and international markets.
Orencia reported revenue of $449 million from its US sales in 2Q17, a 12% rise compared to its revenue of $401 million in 2Q16. In international markets, Orencia reported revenue of $201 million in 2Q17, compared to $192 million in 2Q16.
Overall, Orencia reported revenue of $1.2 billion during the first six months of 2017, a 10.9% rise compared to $1.1 million in the first six months of 2016.
Bristol-Myers Squibb’s revenue from other brands fell ~16% during 2Q17. Its total revenue from other brands was $479 million in 2Q17, compared to $572 million in 2Q16. Its revenue from other brands includes revenue from products that have lost exclusivity in all major markets, over-the-counter brands, and royalties. This revenue fell ~5% to $92 million in the United States in 2Q17, compared to $97 million in 2Q16.
To divest company-specific risks, investors can consider ETFs such as the iShares US Healthcare ETF (IYH), which holds 2.9% of its total assets in Bristol-Myers Squibb. IYH also holds 6.2% of its total assets in Pfizer (PFE), 4.0% in Amgen (AMGN), and 3.1% in Gilead Sciences (GILD).